Clinical trials: Metastatic Malignant Neoplasm to Brain
Brain Neoplasms
IORT After Surgical Resection of Brain Metastases
To evaluate the feasibility and efficacy of the Intraoperative Radiation Therapy (IORT) after the resection of a brain metastases to reduce the incidence of local relapse
- Trial name
- IORT_BRAINM1 (NCT05084092)
- Testing
- Intraoperative Radiotherapy (IORT), Brain surgery
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institut Català d'Oncologia
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma
- Trial name
- NCT01706432
- Testing
- hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Chicago
Advanced Cancer, Brain Metastases
DM-CHOC-PEN for Brain Tumors in AYA Subjects
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03668847
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- DEKK-TEC, Inc.
Brain Metastasis, Bladder Cancer
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
For patients who have one or two metastases in the brain, the tumor(s) can often be removed with surgery to relieve symptoms from the tumor(s) and to improve survival.
- Conditions
- Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer
- Trial name
- NCT00587964
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Estrogen Receptor-Positive
Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients
This study aims to validate a prediction model of brain metastasis risk for females with HR+ breast cancer by using variables collected at diagnosis.
- Trial name
- NCT06729099
- Volunteers
- 128 people
- Sponsor
- Assiut University
Breast Cancer
Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer
Primary objective: To determine the brain response rate of Lipo-Dox in breast cancer patients with brain metastasis Secondary objectives: 1. To determine the overall objective response rate (ORR) 2.
- Trial name
- NCT00465673
- Testing
- Liposomal Doxorubicin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Brain Metastases
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in humans with brain metastases and GBMs.
- Trial name
- NCT01516905
- Testing
- NM404
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Malignant Solid Tumor, Brain Metastasis
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Brain metastasis represents one of the worst prognostic outcomes in advanced malignant tumors. Approximately 10% to 40% of patients with solid tumors develop brain metastases, a incidence rate significantly higher than that of…
- Trial name
- NCT07449481
- Testing
- Utidelone, Bevacizumab
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain Metastases, Radiation Necrosis
REMASTer: REcurrent Brain Metastases After SRS Trial
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic…
- Conditions
- Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
- Trial name
- NCT05124912
- Testing
- Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
- Where
- 9 sites in United States
- Volunteers
- 261 people
- Sponsor
- Monteris Medical
Brain Cancer
Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial
Study Objectives: To compare the survival (overall, systemic, and neurological) of patients with single cerebral metastases treated with either conventional surgical resection or stereotactic radiosurgery.
- Trial name
- NCT00460395
- Testing
- Surgery, Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases, Radionecrosis
FLT-PET / MRI Brain Mets
Brain metastasis (BrM) develops in approximately 40% of cancer patients. Stereotactic radiosurgery (SRS) is a form of radiotherapy that delivers high-dose per fraction to individual lesions that is commonly used to treat BrM.
- Trial name
- NCT04244019
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
NSCLC
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
The purpose of this study is to explore the efficacy and safety of toripalimab combined with anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell Lung Cancer.
- Trial name
- NCT05021328
- Testing
- Toripalimab, Anlotinib, SBRT 7Gy✖️5 QD
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Hubei Cancer Hospital
Cognitive/Functional Effects, Metastatic Cancer
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00910039
- Testing
- sunitinib malate, cognitive assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Malignant Neoplasm in the Brain
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases).
- Trial name
- NCT05438212
- Testing
- Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 216 sites in United States, Canada and 1 more
- Volunteers
- 237 people
- Sponsor
- NRG Oncology
Brain Metastases
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain acceptable in-brain distant control.
- Trial name
- NCT03189381
- Testing
- Cohort A, Cohort B
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Multiple Brain Metastases, Non-small-cell Lung Cancer
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as first-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone. 2.
- Trial name
- NCT01887795
- Testing
- Erlotinib, WBRT
- Where
- China
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Brain Oligometastatic, Non-small Cell Lung Cancer
Brain Oligometastasis in NSCLC
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized.
- Trial name
- OligoLung (NCT07389642)
- Testing
- Standard treatments / multiple strategies
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Bordeaux
Cancer, Metastasis
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and…
- Conditions
- Cancer, Metastasis, Metastatic Cancer, Brain Metastases
- Trial name
- ADORATION (NCT05789589)
- Testing
- Azeliragon, Stereotactic radiosurgery, Corticosteroid
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Baptist Health South Florida
Brain Neoplasm
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
The investigators propose a new treatment strategy of fractionated stereotactic radiosurgery with concurrent bevacizumab for brain metastases.
- Trial name
- NCT02672995
- Testing
- Fractionated stereotactic radiosurgery, bevacizumab
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.